This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases, highlights the ELATIVE® phase 3 clinical trial, which evaluated elafibranor as a potential treatment for primary biliary cholangitis (PBC), a rare and progressive liver disease that can be life-threatening and impact quality of life. The trial aimed to assess how well elafibranor works in addressing this condition, given the limited treatment options currently available.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.